SMITHS FALLS, ON and
MADRID, Sept. 11, 2017 /CNW/ - Canopy Growth Corporation
(TSX:WEED) ("Canopy Growth" or the "Company") and its wholly-owned
subsidiary Spektrum Cannabis GmbH ("Spektrum") are pleased to
announce a supply license agreement with Alcaliber, S.A.
("Alcaliber"), a leading player in the international
pharmaceutical industry based in Spain. Alcaliber specializes in research and
development, breeding and cultivation, and the extraction,
purification and preparation of Narcotic Raw Materials ("NRMs") and
Active Pharmaceutical Ingredients ("APIs"). This agreement is
the first of its kind between a Canadian cannabis company and a
significant, established international pharmaceutical player.
"Entering this agreement with a large, well-recognized European
partner like Alcaliber, with a proven background in controlled
substances and an ability to produce plant-based medication
solidifies our commitment to diversified production capabilities
not just in Canada, but also new
and emerging cannabis markets," said Bruce
Linton, Chairman & CEO, Canopy Growth. "This agreement
gives us additional resources to aggressively enter the European
market where federally permitted by law, while we continue to work
to establish our own complementary production footprint for
cannabis cultivation, value-add oil extraction and Softgel
production in the European Union."
Alcaliber has been granted a license to cultivate, produce,
manufacture, export/import, and commercialize cannabis for medical
and scientific purposes by the Spanish Agency of Medicinal Products
and Medical Devices. As a result of this agreement, Canopy
Growth and Spektrum will grant Alcaliber a license to use certain
strains and seeds to be grown and cultivated at Alcaliber's
facilities for sale worldwide.
"Alcaliber is really enthusiastic about pharmaceutical cannabis
and our agreement with Canopy Growth and Spektrum is a perfect
symbiosis," explained Jose Antonio de la
Puente, CEO, Alcaliber. "There is a clear demand for
pharmaceutical cannabis produced in accordance with pharmaceutical
standards and the expertise we have developed manufacturing
narcotic derivatives for over 40 years combined with Canopy Growth
and Spektrum's cannabis experience will be a great step forward for
the industry."
As a proven global leader in pharmaceuticals with an established
track record of producing NRMs and APIs, as well as existing
production infrastructure and distribution networks in place,
Alcaliber's involvement has the potential to meaningfully expedite
Spektrum's strategic expansion in the European market.
Hacia el crecimiento
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company,
offering distinct brands and curated cannabis varieties in dried,
oil and capsule forms. Through its wholly‑owned subsidiaries,
Canopy Growth operates numerous state-of-the-art production
facilities with over half a million square feet of GMP-certified
indoor and greenhouse production capacity, all to an unparalleled
level of quality assurance procedures and testing. Canopy Growth
has established partnerships with leading sector names in
Canada and abroad, with interests
and operations spanning four continents. The Company is proudly
dedicated to educating healthcare practitioners, providing
consistent access to high quality cannabis products, conducting
robust clinical research, and furthering the public's understanding
of cannabis. For more information visit www.canopygrowth.com.
About Spektrum Cannabis Gmbh
Spektrum Cannabis GmbH
distributes cannabis medicine products to hundreds of pharmacies
across Germany. Spektrum's
facility in Germany is GMP
certified by the relevant authority, Regierungspräsidium Tübingen,
making it, to the Company's knowledge, the only GMP-certified
cannabis processing facility in Germany.
About Alcaliber
Alcaliber S.A. is a Spanish company
founded in 1973 with an overall industrial focus, dedicated to
guaranteeing the supply of narcotic raw materials, based on the
cultivation in Spain of the opium
poppy and its subsequent transformation into concentrate poppy
straw, as well as the extraction of its alkaloids. Alcaliber holds
a leading position in the international industry. With over 80% of
production destined for export, its products are a benchmark in
terms of safety and quality. Learn more by visiting
www.alcaliber.com
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but
not always, forward-looking statements can be identified by the use
of words such as "plans", "expects" or "does not expect", "is
expected", "estimates", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of Canopy Growth Corporation, Tweed
Inc., Tweed Farms Inc., Mettrum Health Corp., or Bedrocan Canada
Inc. to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Examples of such statements include
future operational and production capacity, the impact of enhanced
infrastructure and production capabilities, and forecasted
available product selection. The forward-looking statements
included in this news release are made as of the date of this news
release and Canopy Growth Corp. does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
Neither the TSX Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Canopy Growth Corporation